Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00110396 · ClinicalTrials.gov registry record · Phase 3
Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis
A Phase 3 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 3
- Development phase
- 260
- Enrollment target
NCT00110396 is a Phase 3 study that has completed, run by EMD Serono. The registered enrollment target is 260 participants.
The verdict
NCT00110396, a Phase 3 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 260 participants
- Enrollment target
Study Summary
The primary objective of the study is to compare the immunogenicity of the new fetal bovine serum (FBS)-free/human serum albumin (HSA)-free Rebif® formulation (RNF) to historical data.
Interventions
- BIOLOGICAL Interferon-beta-1a FBS-free/HSA-free
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2005-01 |
| Est. Completion | 2007-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00110396
The ClinicalTrials.gov registry entry for NCT00110396 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 260 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Interferon-beta-1a FBS-free/HSA-free is the first listed.
NCT00110396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00110396 about?
NCT00110396 is a clinical study titled "Rebif New Formulation (RNF) in Relapsing Forms of Multiple Sclerosis". The primary objective of the study is to compare the immunogenicity of the new fetal bovine serum (FBS)-free/human serum albumin (HSA)-free Rebif® formulation (RNF) to historical data.
What is the current status of trial NCT00110396?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 260 participants. The study started on 2005-01. Estimated completion is 2007-04.
What interventions are being tested in trial NCT00110396?
The interventions under investigation include: Interferon-beta-1a FBS-free/HSA-free (BIOLOGICAL).
Who is sponsoring clinical trial NCT00110396?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.